Journal ArticleOPEN ACCESS

Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review

  • Luo J
  • Florez N
  • Donnelly A
  • et al.
JCO Precision Oncology (2024) (8)
DOI: 10.1200/po.23.00644
10Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

PURPOSEKRAS is the most commonly mutated driver oncogene in non–small cell lung cancer (NSCLC). Sotorasib and adagrasib, KRASG12C inhibitors, have been granted accel...

Cite

CITATION STYLE

APA

Luo, J., Florez, N., Donnelly, A., Lou, Y., Lu, K., Ma, P. C., … Husain, H. (2024). Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precision Oncology, (8). https://doi.org/10.1200/po.23.00644

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free